While at QED, Dr. Tobia was acting president of Arcturus Pharmaceutical Co., a dermatology company founded by three Harvard dermatologists and funded by several Boston venture capitalists. Before starting QED with her partners, she was senior vice president and general counsel and founder of British Technology Group, USA (BTG), one of the world's leading technology transfer and licensing companies, as well as managing director of its parent company, BTG plc, a United Kingdom-based company. Prior to that she was counsel to the president of the Bristol Myers Institute for Medical Research, where she structured strategic alliances with biotech companies and academic institutions. She started her career as a post-doctoral fellow at Rockefeller University, where she was an American Cancer Society Fellow, and then earned her law degree from Rutgers University, Newark, NJ.

Robert Kahn, Chief Operating Officer-Dynamis Skin Science  
Mr. Kahn has extensive financial and operations background in the chemical, adhesive, cosmeceutical, and cosmetic markets. Most of his career was with Henkel, a German-based multi-billion company with a focus on consumer products, including cosmetics. Since leaving Henkel, Mr. Kahn has served as a consultant to various firms in the area, including Fallene Ltd, with experience in the dermatologist, spa, and consumer markets. Mr. Kahn is a graduate of the Wharton School at the University of Pennsylvania and has a master's degree from Cornell University.

Frank Kappler, Ph.D., Scientist  
Dr. Kappler was a co-founder and is currently a scientific officer of the Company. Dr. Kappler has a Ph.D. in organic chemistry and has formulated all of the Dynamis products to date. Dr. Kappler also isolated and purified fructosamine-3-kinase, the enzyme that is the basis for Dynamis' platform technology. He has designed and synthesized several meglumine analogs that are more potent inhibitors of fructosamine-3-kinase than is meglumine. Dr. Kappler makes frequent presentations at national and international scientific meetings and has authored more than 80 scientific publications and 12 patents.

Alice Marcy, Ph.D., Scientist and Director of Licensing  
Dr. Marcy joined Dynamis in February 2005. She is an experienced scientist and manager with a graduate degree from Johns Hopkins University and a postdoctoral fellowship from Harvard Medical School. Dr. Marcy has 12 years of laboratory research experience as a biochemist/molecular biologist doing basic drug discovery at Merck. Just prior to joining Dynamis, Dr. Marcy held a position to identify and evaluate in-licensing opportunities for Merck and concluded several licensing and research collaboration deals totaling in excess of $300 million. Dr. Marcy will oversee the Company's Medical Advisory Board.

Bangying Su, Ph.D., Scientist  
Dr. Su is the Director of Chemistry at Dynamis and is a graduate of Beijing University in China. She was employed at the Academica Sinica in Beijing for twenty years. She won several awards from the government and military for her work in both natural products and photographic chemicals. Dr. Su came to the United States in 1988 and worked at Washington University in Saint Louis and then The University of Alabama at Birmingham before coming to Fox Chase to work with Dr. Kappler. Dr. Su has been instrumental in the development, synthesis, and testing of the Dynamis' proprietary compounds. Dr. Su joined Dynamis full-time in September 2002.

Medical Advisory Board

Felix M. Barker II, O.D., M.S.  
Dr. Felix M. Barker is professor of optometry and research director at the Pennsylvania College of Optometry (PCO). Professor Barker received his doctorate in 1973 from Indiana University and his masters in vision science in 1979 from the University of Houston. Professor Barker joined the PCO faculty in 1978 after completion of his graduate studies and his military service as an army optometry officer. He is the former director of medical education of the Eye Institute at PCO and has served on the Optometric Accreditation Council of the American Optometric Association and on the Board of Pharmaceutical Specialties of the American Pharmaceutical Association. He was recently elected a distinguished practitioner of the National Academy of Practice of Optometry.

ADDITIONAL MEMBERS OF THE MEDICAL ADVISORY BOARD ARE BEING RECRUITED

Cosmetic Advisors

Richard H. Wildnauer, Ph.D., M.B.A.  
Dr. Wildnauer was formerly president of NeoStrata Company, a private skincare firm which originated the use of alpha hydroxyl acids in skin lotions. Prior to NeoStrata, he spent 25 years at Johnson & Johnson in senior executive positions in R&D and business/market development at three J&J operating companies (Janssen Pharmaceuticals, McNeil Pharmaceutical, and J&J Domestic) and J&J Corporate.

William H. Schmitt  
Mr. Schmitt was formerly senior vice president of R&D for Unilever-NA, a $4.5 billion division of Unilever. He previously served as Vice President of Research and Development for Elizabeth Arden and as a Director of Research, Domestic Division with Chesebrough Pond's. Mr. Schmitt served as Chairperson of The Cosmetic, Toiletry and Fragrance Association's Scientific Advisory Board, and received the Robert Ring Lifetime Achievement Award for service to the industry. He is the holder of numerous patents in his field.

Financial Advisor

James A. Meer, M.B.A.  
Mr. Meer is currently senior vice president, CFO and treasurer of Columbia Laboratories, a publicly traded biotech company which he joined in 2006. From 2004 to 2006, he was CFO at Pharmos Corporation. Prior to Pharmos, he was a principal in Meer Healthcare Consulting and Grey Peach Partners serving life science and technology companies. From 1992 to 2000, Mr. Meer was vice president and treasurer of Schein Pharmaceutical, Inc, (NYSE) a leading specialty pharmaceutical company. In addition, Mr. Meer has held several senior financial positions with public companies in other industries. He holds an MBA in Finance from Pace University and a BA in Economics from Rutgers College.

Board Of Directors

Annette M. Tobia, Ph.D., J.D., President and CEO, Director

Oliver Franklin, Director  
Mr. Franklin has an extensive record of public service, highlighted by his tenure as the Deputy City Representative for the City of Philadelphia, where he created the Office of Arts and Culture and doubled municipal arts funding. He is the co-founder and president of Reinvest In South Africa (RISA) Investment Advisors, LLC. He also serves as a trustee of the Rosenbach Museum and Library, the South African Environmental Trust, the International House of Philadelphia, and the Sir Hans Koopler Trust in New York and London. He is a member of the Bank of America Philadelphia Advisory Board and serves as president of the Philadelphia Chapter of the Oxford & Cambridge Society. The Greater Philadelphia Chamber of Commerce also appointed Oliver Franklin to the Foundation's Board. Mr. Franklin has also served as the Philadelphia's Chief of Protocol and created Philadelphia's international marketing efforts. Mr. Franklin was a senior vice president with Boston's Fidelity Management Trust Co. In January 2002, Oliver received the Most Excellent Order of the British Empire (OBE) commendation for exceptional achievement. He is also the Honorary British Consul in Philadelphia.

Kevin W. Kimmel, C.P.A., M.S.T., Director, Corporate Secretary & Treasurer  
Kevin received his B.S. in accounting from Albright College in 1984 and his Masters in taxation from Widener University in 1994. He is also a certified public accountant. Kevin was a partner in Kimmel, Lorah and Associates CPAs LLP in Valley Forge, PA. prior to forming his own business consulting practice. Kevin's experience in financial audits, corporate taxation, and general business planning has served clients spanning the spectrum in size and industry. In addition, he is a director and treasurer of several closely held companies. Kevin is a member of the American Institute of CPAs and Pennsylvania Institute of CPA's.